Thyroid Cancer Overdiagnosis: Are We Treating What Doesn’t Need Treatment? Abstract Background and Purpose:The global incidence of thyroid cancer has risen sharply over the past three decades. Data indicate that annual incidence increased from 5.0 cases per 100,000 individuals in 1975 to 14.6 cases per
Oncology
Venetoclax-based Regimens in AML: The New Standard or a Temporary Fix?
Venetoclax-based Regimens in AML: The New Standard or a Temporary Fix? Abstract Acute myeloid leukemia (AML) remains a challenging hematologic malignancy, particularly among older adults and patients unfit for intensive chemotherapy. Over the past decade, treatment models have shifted with the advent of venetoclax, a selective BCL-2 inhibitor,
BTK Inhibitors in CLL: New Clinical Evidence Reshapes First-Line Treatment
BTK Inhibitors in CLL: New Clinical Evidence Reshapes First-Line Treatment Please like and subscribe if you enjoyed this video :-) Introduction The treatment landscape for chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries, has undergone a major shift with the advent of Bruton’s tyrosine kinase
Monoclonal Antibodies in Relapsed Multiple Myeloma: The Era of Bispecifics and Beyond
Monoclonal Antibodies in Relapsed Multiple Myeloma: The Era of Bispecifics and Beyond Check back later for a possible video summary. Videos are created for most articles. Abstract This paper provides an in-depth review of monoclonal antibody (mAb) therapies in the treatment of relapsed multiple myeloma (MM), with a particular focus on bispecific antibodies
Hidden Signs of GATA2 Deficiency: Why Doctors Miss This Rare Disorder
Hidden Signs of GATA2 Deficiency: Why Doctors Miss This Rare Disorder Check back later for a possible video summary. Videos are created for most articles. Introduction GATA2 deficiency is the most common hereditary predisposition to pediatric myelodysplastic syndrome (MDS), yet it remains one of the most frequently overlooked genetic disorders in clinical practice. This
Cancer Vaccines for Treatment: Breaking Through Scientific Barriers in 2025
New Anticoagulants vs LMWH in Cancer-Associated Thrombosis: Latest Evidence
New Anticoagulants vs LMWH in Cancer-Associated Thrombosis: Latest Evidence Please like and subscribe if you enjoyed this video :-) Introduction Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains one of the most common and life-threatening complications in patients with cancer.
JAK2, CALR, and MPL Mutations: Advanced Treatment Strategies That Work
Breaking the Myth: Delayed Intensification Side Effects in Modern ALL Treatment (2025 Update)
AI Blood Cancer Detection: 92% Accuracy in New Clinical Study
